Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (201-210 of 304) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.
Biomicrofluidics|December 24, 2015
High efficiency vortex trapping of circulating tumor cellsManjima Dhar, Jessica Wong, Armin Karimi, et al.
Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.
Tetrahedron|October 23, 2018
Further studies on the application of vinylogous amides and β-halovinylaldehydes to the regiospecific synthesis of unsymmetrical, polyfunctionalized 2,3,4- and 1,2,3,4- substituted pyrrolesJohn T Gupton, Alex Shimozono, Evan Crawford, et al.
Annals of the Rheumatic Diseases|May 11, 2025
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLEEduardo Gómez-Bañuelos, Alessandra Ida Celia, Maria Isabel Trejo-Zambrano, et al.
JAMA Oncology|January 11, 2024
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialTrudy C Wu, Elaine Luterstein, Beth K Neilsen, et al.
Journal of Hematology & Oncology|March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast CancerTimothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Pageof 31

Showing results (201-210 of 304) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.
Biomicrofluidics|December 24, 2015
High efficiency vortex trapping of circulating tumor cellsManjima Dhar, Jessica Wong, Armin Karimi, et al.
Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.
Tetrahedron|October 23, 2018
Further studies on the application of vinylogous amides and β-halovinylaldehydes to the regiospecific synthesis of unsymmetrical, polyfunctionalized 2,3,4- and 1,2,3,4- substituted pyrrolesJohn T Gupton, Alex Shimozono, Evan Crawford, et al.
Annals of the Rheumatic Diseases|May 11, 2025
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLEEduardo Gómez-Bañuelos, Alessandra Ida Celia, Maria Isabel Trejo-Zambrano, et al.
JAMA Oncology|January 11, 2024
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialTrudy C Wu, Elaine Luterstein, Beth K Neilsen, et al.
Journal of Hematology & Oncology|March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast CancerTimothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Pageof 31